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ABSTRACT
Objective: To evaluate the destruction complex of beta-catenin 
by the expression of the proteins beta-catetenin, adenomatous 
polyposis coli, GSK3β, axin and ubiquitin in colorectal carcinoma 
and colonic adenoma. Methods: Tissue samples from 64 patients 
with colorectal carcinoma and 53 patients with colonic adenoma 
were analyzed. Tissue microarray blocks and slides were prepared 
and subjected to immunohistochemistry with polyclonal antibodies in 
carcinoma, adjacent non-neoplastic mucosa, and adenoma tissues. 
The immunoreactivity was evaluated by the percentage of positive 
stained cells and by the intensity assessed through of the stained 
grade of proteins in the cytoplasm and nucleus of cells. In the 
statistical analysis, the Spearman correlation coefficient, Student’s 
t, χ², Mann-Whitney, and McNemar tests, and univariate logistic 
regression analysis were used. Results: In colorectal carcinoma, 
the expressions of beta-catenin and adenomatous polyposis coli 
proteins were significantly higher than in colonic adenomas (p<0.001 
and p<0.0001, respectively). The immunoreactivity of GSK3β, 
axin 1 and ubiquitin proteins was significantly higher (p=0.03, 
p=0.039 and p=0.03, respectively) in colorectal carcinoma than 
in the colonic adenoma and adjacent non-neoplastic mucosa. The 
immunohistochemistry staining of these proteins did not show 
significant differences with the clinical and pathological characteristics 
of colorectal cancer and colonic adenoma. Conclusions: These results 
suggest that, in adenomas, the lower expression of the beta-catenin, 
axin 1 and GSK3β proteins indicated that the destruction complex 
of beta-catenin was maintained, while in colorectal carcinoma, the 
increased expression of beta-catenin, GSK3β, axin 1, and ubiquitin 
proteins indicated that the destruction complex of beta-catenin was 
disrupted.
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RESUMO
Objetivo: Avaliar o complexo de destruição da betacatenina no 
carcinoma colorretal e no adenoma do colo pela expressão das 
proteínas betacatenina, adenomatous polyposis coli, GSK3β, axina 
e ubiquitina. Métodos: Amostras de tecidos de 64 doentes com 
carcinoma colorretal e de 53 pacientes com adenoma do colo foram 
analisadas. Blocos de tecidos foram submetidos ao estudo imuno-
histoquímico com anticorpos policlonais nos tecidos do carcinoma, 
mucosa não neoplásica adjacente e adenoma. A imunorreatividade 
foi avaliada pela porcentagem de positividade de células coradas e 
pela intensidade do grau de coloração das proteínas no citoplasma 
e no núcleo das células. Na análise estatística, foram utilizados o 
coeficiente de correlação de Spearman, os testes t de Student, 
χ², Mann-Whitney e de McNemar, e a análise de regressão logística 
univariada. Resultados: No carcinoma colorretal, as expressões da 
betacatenina e da adenomatous polyposis coli foram significativamente 
maiores do que em adenomas do colo (p<0,001 e p<0,0001, 
respectivamente). A imunorreatividade das proteínas GSK3β, axina 
1 e ubiquitina foi significativamente maior (p=0,03, p=0,039 
e p=0,03, respectivamente) no carcinoma colorretal do que no 
adenoma e na mucosa não neoplásica adjacente. A coloração 
imuno-histoquímica dessas proteínas não apresentou diferenças 
significantes em relação às características clinicopatológicas do 
câncer colorretal e do adenoma. Conclusões: Em adenomas, as 
menores expressões de betacatenina, axina 1 e GSK3β indicaram 
que o complexo de destruição da betacatenina estava conservado, 
enquanto que, no carcinoma colorretal, o aumento das expressões da 
betacatenina, GSK3β, 1 axina, e ubiquitina indicaram que o complexo 
de destruição de betacatenina estava alterado.
Descritores: Neoplasias colorretais; Adenoma; Imuno-histoquímica; 
beta Catenina; Genes APC; Glicogênio sintase; Proteína axina; Ubiquitina; 
Via de sinalização Wnt
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cancers, including hepatocellular carcinoma, colorectal 
carcinoma, lung cancer, malignant breast tumors, and 
ovarian and endometrial carcinomas.(6)
Excess cytoplasmic beta-catenin is incorporated into 
multi-subunit complex which includes the destruction 
of proteins axin 1, adenomatous polyposis coli (APC), 
casein kinase 1 (CK1), and glycogen synthase kinase 
3β (GSK3β).(4) In the absence of a Wnt signal, beta-
catenin binds to the APC tumor suppressor protein 
and this protein is recruited to the destruction complex, 
which promotes its phosphorylation by axin, CK1 
and GSK3β.(1,3,4,6) The phosphorylation of beta-catenin 
by GSK3β leads to its ubiquitination forming the 
complex polyubiquitin/beta-catenin and, subsequently, 
is degraded into the proteasome.(4,6) The mutation 
of genes correspond to the formation of the complex 
destruction of the beta-catenin protein and triggers 
a cascade of events that lead to the disruption of 
the APC/axin 1/GSK3β complex and accumulation 
of unphosphorylated beta-catenin in the cytoplasm.(1,4) 
Then, the beta-catenin stabilized protein translocates 
into the nucleus, in which it activates the expression 
of a range of genes in association with the T-cell factor 
(TCF) and the lymphoid-enhancing factor (LEF), both 
transcription factors, that, in turn, activate the target 
genes that are related to carcinogenesis (Figure 1).(1,3,4)
INTRODUCTION
All cells exist under strict regulation of signals for 
growth, apoptosis, differentiation, cell-cell interactions 
and cell-extracellular matrix interactions.(1) Colorectal 
cancer (CRC) is considered the result of the cumulative 
effect of multiple mutations within the cell that allow 
it to escape growth control and regulatory mechanisms.(1,2) 
It has become apparent that the accumulation of 
gene mutations in a clonal cell results in the transition 
from the normal colon epithelial cell into colorectal 
carcinoma.(3) 
Beta-catenin, a member of the catenin protein family, 
is a dual-function protein that regulates the coordination 
of cell-cell adhesion and gene transcription.(4) Beta-
catenin is a subunit of the cadherin protein complex 
and acts as an intracellular signal transducer in the 
Wnt signaling pathway.(3,4) The canonical Wnt signaling 
pathway, acting through beta-catenin, modulates a 
variety of cellular processes, including proliferation, 
survival, apoptosis, differentiation, cell adhesion and 
motility.
The Wnt effector beta-catenin is a transcriptional 
co-activator that can also mutate to a potent oncogene, 
while the canonical Wnt signaling pathway stabilizes 
beta-catenin transcription.(4,5) Mutations and the 
overexpression of beta-catenin are associated with many 
LRP: lipoprotein receptor-related protein; Dsh: Dishevelled; APC: adenomatous polyposis coli; GSK3β: axin/glycogen synthase kinase 3β; LEF: lymphoid enhancing factor; TCF: T-cell factor.
Figure 1. The Wnt/beta-catenin signaling pathway. (A) In the presence of the destroyer complex, beta-catenin is degraded via adenomatous polyposis coli/axin/
glycogen synthase kinase 3β. (B) When the binding of beta-catenin with the complex by destroying not occurs, then the beta-catenin is not phosphorylated and this 
protein penetrates the cell nucleus. Inside the nucleus, the beta-catenin binds to the transcription factor target genes lymphoid enhancing factor/T-cell factor to 
promote carcinogenesis
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The so-called adenoma-carcinoma sequence nowadays 
still represents the paradigm and the support of our 
understanding of the molecular and genetic basis of 
this disease. In human CRC, Wnt signaling activation is 
hypothesized to be the key event for adenoma initiation, 
whereas additional mutations are required for the 
progression from adenoma to carcinoma.(2-4) A large 
body of evidence has suggested that aberrant activation 
of Wnt signaling following APC loss is a major cause 
of colon adenoma formation.(4-6) Loss-of-function and 
gain-of-function studies of Wnt proteins and beta-
catenin have suggested that aberrant Wnt signaling 
activation after APC loss is responsible for the initiation 
of intestinal adenoma.(3,7) Therefore, hyperactivation of 
Wnt signaling is generally viewed as the key event for 
the initiation of intestinal adenoma after APC loss.(4,8) 
An important step is to elucidate the molecular 
mechanisms underlying the cooperative functions of 
Wnt signaling, which may lead to the identification 
of novel therapeutic targets for the prevention and 
treatment of gastrointestinal cancer.(6,8)
The genetic mutations accumulated during tumor 
development are responsible for the deregulation of 
key signal transduction pathways, such as Wnt, which 
is responsible for uncontrolled cell growth, inhibition of 
apoptosis, and immortalization.(2,4,5) Still, little is known 
about the multiple interactions and mutual influences 
of this defective pathway, and about the mechanisms 
responsible for the genetic instability contributing 
to the establishment of the multiple genetic defects 
that are necessary to promote tumor progression and 
malignancy.(1,2,4)
By defining the molecular alterations involved in 
the development of the sporadic CRC, it is possible to 
expect the achievement of specific molecular targeting 
for the treatment of already-established tumors, as well 
as for chemoprophylaxis interventions.(7,8)
OBJECTIVE
To evaluate the destruction complex of beta-catenin by 
the expression of beta-catetenin, adenomatous polyposis 
coli, glycogen synthase kinase 3β, axin, and ubiquitin 
proteins in colorectal carcinoma and colonic adenoma. 
By defining this protein alterations of the Wnt signaling 
pathway involved in the adenoma and colorectal cancer, 
we can to expect the achievement of specific molecular 
targeting for the treatment of already established tumors. 
METHODS
This is an observational, longitudinal and retrospective 
study. A total of 64 patients with CRC and 53 patients 
with colonic adenoma were studied. Between 2006 and 
2010, 64 patients with CRC were consecutively submitted 
to curative surgery with resection of their colorectal 
tumors. Patients with colonic adenoma underwent the 
removal of their adenomas by colonoscopy.
The inclusion criteria were adult patients with 
CRC or colorectal adenoma confirmed by histological 
analysis. Exclusion criteria were the presence of colorectal 
hereditary nonpolyposis neoplasm (Lynch syndrome), 
CRC associated with inflammatory bowel disease, and 
intestinal polyposis syndromes.
In patients submitted to surgery for CRC, 64 tissue 
samples were obtained from the tumor and from 
adjacent non-neoplastic colorectal mucosa, located 
10cm from the upper margin of the neoplasm. In the 53 
patients with colonic adenomas, there were 71 resected 
adenomas.
Among the patients operated with CRC, 33 (51.6%) 
were females. The median age was 69.2±7.4 years (51 
to 90 years). The location of the CRC was in the colon 
in 38 (59.4%) patients and in the rectum in 26 (40.6%).
Regarding the adenomas, 27 (50.9%) patients were 
male. The median age was 60.7±3.4 years (29 to 88 
years). The location of the adenomas was 46 (86.8%) 
in the left colon and 7 (13.2%) in the right colon. There 
were no rectal adenomas.
Within patients with CRC, information was recorded 
regarding the location, size, level of invasion in the 
intestinal wall, inflammatory infiltrate degree, lymph 
node involvement, degree of tumor differentiation, 
lymphatic-vascular-neural invasion, Classification of 
Malignant Tumours (TNM),(9) presence of synchronous 
metastases, and immunostaining (staining intensity and 
percentage of stained cells scores) of the antibodies 
that were used in the colorectal tissue. In patients with 
colonic adenoma, statistics were recorded regarding the 
morphological characteristics of the neoplasm (location, 
histological type, and degree of cell atypia) and the 
immunostaining (staining intensity and percentage of 
stained cells scores) in the colonic tissue.
The tissues were fixed in formalin and routinely 
processed by using the paraffin-embedding method 
for histological analysis. Histological sections with 3µ 
thickness were obtained from each block. All slides 
were stained with hematoxylin-eosin (HE) and revised 
by the pathologist for confirmation of the diagnosis.
In the stained slides, the areas of the tumor were 
identified for the preparation of tissue microarray 
(TMA). The TMA block was prepared by using 
Beecher™ (Beecher Instruments, Silver Spring, MD, 
USA) equipment, in according to the previously 
described protocol that was used in our laboratory.(10) 
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The paraffin blocks were cut 3µm thick, and the slides 
were prepared for immunohistochemical study. The 
antibodies which were used included: rabbit polyclonal 
primary anti-beta-catenin; rabbit polyclonal anti-
APC; rabbit polyclonal primary anti-GSK3β; rabbit 
polyclonal primary anti-axin; mouse polyclonal primary 
anti-ubiquitin (all from Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). All antibodies were used at a 
dilution of 1:100. The positive controls used included 
normal colon tissue for APC and axin, HeLa whole-
cell lysate for GSK3β and ubiquitin, and human colon 
cancer for beta-catenin. A similar slide was used as a 
negative control, subtracting the primary antibody from 
the reaction.
The anti-beta-catenin, anti-APC and anti-GSK3β 
antibodies were used in CRC tissue, colonic adenoma 
and in adjacent non-neoplastic mucosa. The anti-axin 
and anti-ubiquitin antibodies were used in CRC tissue 
and adjacent non-neoplastic mucosa (Figure 2).
The immunoexpression score was prepared according 
to the method described by Hao et al.(6) Positivity 
was considered to be a score zero if less than 5% of 
epithelial cells were stained in the neoplasm; a score 1 
if there was 5% to 25%; a score 2 if there was 26% to 
50%; a score 3, if there was 51% to 75%; and a score 
4, if more than 75% of epithelial cells were stained 
in the neoplasm. The intensity was considered to be 
score zero when there were no stained cells; a score 1 
when the stain was weak; a score 2 when the stain was 
moderate; and a score 3 when the intensity of stained 
cells was strong. The final score of immunoexpression, 
which varied between zero and 12, was obtained by 
multiplying the scores of intensity and positivity. The 
immunoexpression was classified as reduced when the 
final score was among zero and 8, and strong if the final 
score was among 9 and 12.
All slides were analyzed by two well-trained, 
independent researchers who had no access to any 
pathological information. The final score (zero to 12) 
was the result of a mean score by the researches. In most 
cases, there was agreement between the two evaluations 
of the final score. When there was not agreement, a 
consensus score was adopted.
The loss by technical failure or inconclusive results has 
made it impossible to evaluate the immunohistochemical 
study of some samples, and these events were the reasons 
why they were excluded from the study.
The quantitative results were described as the mean 
and standard deviation. Qualitative data were described 
as frequencies. The correlation between the scores of 
the immunohistochemical expression of the proteins 
with the clinicopathological parameters was calculated 
by Spearman’s correlation coefficient. The Student’s 
t, χ², Mann-Whitney and McNemar tests were used to 
assess the significance of the differences in the clinical 
and pathological parameters, and associations with 
proteins’ immunoexpression. The univariate logistic 
regression analysis (Analysis of Variance − ANOVA) 
and multivariate analysis were used to identify the 
dependent and independent variables. The statistical 
significance level was set at 5% (p<0.05), and the 
data were analyzed using the Statistical Package for 
Social Sciences® software (SPSS®, Chicago, IL, USA), 
version 17.0. 
The present study was conducted according to the 
ethical principles of the Declaration of Helsinki from 
Figure 2. Photomicrographs of the immunohistochemical staining of the proteins represented by the brownish color in the cytoplasm of cells. Beta-catenin (A – colonic 
adenoma, 200X; B – colorectal carcinoma, 200X); adenomatous polyposis coli (C – colonic adenoma, 200X; D – colorectal carcinoma, 200X); GSK3β (E – colonic 
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the World Medical Association and has been approved 
by the Research Ethics Committees of our institution, 
CAAE: 0042.0.338.000-09.
RESULTS
In terms of CRC, the average tumor size was 5.2±1.3cm 
(0.5 to 12cm). The size of the tumor along its longest 
axis was >5cm in 43 (67.1%) patients and ≤5cm in 
21 (32.8%). Lymph node metastasis was found in 31 
(48.4%) patients. The invasion of blood vessels was 
observed in 21 (32.8%) patients, lymphatic vessel 
invasion in 24 (37.5%) and neural invasion in 12 (18.7%). 
Eleven (17.2%) carcinomas were well differentiated; 
51 (79.7%), moderately differentiated; and 2 (3.1%), 
poorly differentiated. The CCR superficially infiltrated 
(T1 + T2) the intestinal wall in 18 (28.1%) patients 
and deeply (T3 + T4) in 46 (71.9%). The presence of 
synchronous metastases was observed in 14 (21.9%) 
patients. Relapse occurred in 13 (20.3%) patients and 
12 (18.7%) of them died for this reason. The average 
follow-up time was 19.1±2.8 months (3 to 36 months).
The average size of the polyps was 0.6±0.2cm (0.4 to 
1.7cm). The polyps were <1.0cm in 34 (64.1%) patients 
and ≥1.0cm in 19 (35.8%). The histological type of 
adenoma was tubular in 49 (69%) and tubular-villous 
in 22 (31%). Moderate atypia were found in 39 (55%) 
adenomas and mild atypia was noted in 32 (45%).
 The expression of beta-catenin protein in CRC was 
significantly (p<0.001) higher than in the adenomas 
and significantly (p<0.001) higher than in the adjacent 
non-neoplastic mucosa. This increased beta-catenin 
expression occurred mainly in the cytoplasm of cells, but 
nuclear staining was also significant. In adenomas, the 
staining of beta-catenin was significantly (p<0.0001) 
lower than in adjacent non-neoplastic mucosa (Table 1).
The immunoreactivity of the APC protein in CRC 
was significantly (p<0.0001) higher than in the adenoma. 
The APC protein immunoreactivity in the adjacent 
non-neoplastic mucosa was significantly (p<0.0001) 
higher than in the adenoma. There was no significant 
difference (p=0.24) between the immunoreactivity 
of the APC protein in CRC and in its adjacent non-
neoplastic mucosa.
The immunoreactivity of the GSK3β protein in 
adenoma was significantly lower in the CRC and in the 
adjacent non-neoplastic mucosa (p=0.03 and p=0.0005, 
respectively). There was no significant difference (p=1.00) 
between the immunoreactivity of GSK3β protein in 
CRC and in the adjacent non-neoplastic mucosa.
Table 1. Immunohistochemical staining of beta-catenin, adenomatous polyposis coli glycogen synthase kinase 3β (GSK-3β), axin 1 and ubiquitin in colorectal carcinoma, 
adjacent non-neoplastic mucosa, and colonic adenoma
Protein Grade of immunohistochemical stained
CRC Adjacent non-neoplastic mucosa Adenoma p value
n (%) n (%) n (%)
Beta-catenin 50 (78.1) 44 (68.7) 53 (74.6) <0.001* (tumor versus adenoma)
Strong 37 (74.0) 22 (50.0) 8 (15.1) <0.001* (tumor versus mucosa)
<0.0001* (adenoma  versus mucosa)
Reduced 13 (26.0) 22 (50.0) 45 (84.9)
APC 42 (65.6) 42 (65.6) 53 (74.6) <0.0001* (tumor versus adenoma)
0.24, NS (mucosa versus tumor)
<0.0001* (adenoma  versus mucosa)
Strong 38 (90.4) 41 (97.6) 24 (45.2)
Reduced 4 (9.5) 1 (2.4) 29 (54.7)
GSK3β 54 (84.4) 54 (84.4) 46 (70.4) 0.0005* (tumor versus adenoma)
1.00, NS (tumor versus adenoma)
0.0005* (adenoma versus mucosa)
Strong 46 (85.2) 46 (85.2) 6 (13.1)
Reduced 8 (14.8) 8 (14.8) 40 (86.9)
Axin 1 61 (95.3) 49 (76.5) 0.04*
Strong 34 (55.7) 13 (26.5)
Reduced 27 (44.3) 36 (73.4)
Ubiquitin 48 (75.0) 48 (75.0) 0.3, NS
Strong 18 (37.5) 29 (60.4)
Reduced 30 (62.5) 19 (39.6)
* Significant. CRC: colorectal carcinoma; NS: non significant; APC: adenomatous polyposis coli.
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The immunoreactivity of axin 1 protein was significantly 
(p=0.039) lower in the adjacent non-neoplastic mucosa. 
The expression of ubiquitin showed a significant difference 
(p=0.03) between the CRC and the adjacent non-
neoplastic mucosa.
The immunohistochemical expression of beta-
catenin protein APC, GSK3β, axin 1 and ubiquitin 
in colorectal adenomas and CRC did not show 
significant differences with the clinical and pathological 
characteristics of CRC and colonic adenoma.
DISCUSSION
In humans, the beta-catenin protein is encoded by 
the gene CTNNB1, which maps at 3p22.1 (3,5). Hao 
et al.(6) demonstrated an aberrant expression of beta-
catenin mutations in the CCR, and this is an early event 
in human colorectal carcinogenesis. These authors 
verified that the adjacent normal epithelium to aberrant 
crypts showed a strong staining of beta-catenin, an 
event that was also observed in this study in CRC and in 
its adjacent non-neoplastic mucosa, but not in colonic 
adenomas.
The APC gene maps at position 21q in chromosome 
5 and encodes a protein with multiple functional 
domains that interact with proliferation and apoptosis 
regulators.(11,12) The gene is mutated in 63% of sporadic 
adenomas and in over than 80% of sporadic CRC. 
The heterozygous mutation is inherent in all cases 
of familial adenomatous polyposis.(13-15) The APC 
protein forms molecular complexes that are capable 
of eliminating the intra-cytoplasmic beta-catenin, 
inducing its degradation.(1,4,12) In the epithelium of the 
large intestine, APC expression is restricted to regions 
in which cell replication has ceased, and terminal 
differentiation was established.(13)
In the large intestine, isolated mutations in the 
APC gene are sufficient to provide a selective growth 
advantage, by reducing the function of the APC-
specific degree sufficient to allow the accumulation of 
nuclear beta-catenin, promoting the cell proliferation 
without causing excessive apoptosis.(2,3,12) Thus, since 
the physiological role of the APC protein is a growth 
advantage, the loss of its function will promote a 
cellular clonal expansion.(11,12) When the APC protein 
is mutated, it loses its binding site in the complex 
destruction of beta-catenin, which causes an increased 
expression of beta-catenin protein in the cytoplasm and 
nucleus.(15-17)
Li et al.(18) examined the expression of APC and 
mutated in CRC proteins, the key regulators of beta-
catenin, by immunohistochemistry in right-sided serrated 
polyps. This study implied that the molecular-specific 
form of beta-catenin may participate in the Wnt-signaling 
activation of right-sided serrated polyps. Moreover, 
the loss of mutated in colorectal protein but not APC 
expression may contribute to the early activation of Wnt 
signaling in right-sided serrated polyps. In the present 
study, a decreased immunoreactivity of the non-mutated 
APC protein was observed in most patients with colonic 
adenomas. On the other hand, the significant presence 
of non-mutated APC protein in CRC and in adjacent 
non-neoplastic mucosa may indicate that the mutated 
APC protein is not involved as an important component 
in the process of carcinogenesis in these specific 
tumors. Wong et al.(19) studied 758 cases of colorectal 
adenomas and concluded that the malignant conversion 
of adenomas may not be related to the mutation of the 
APC gene alone. Thus, the development of colorectal 
carcinogenesis, even in the absence of the APC-mutated 
protein, is possible, as the results of the present study 
also suggested.
The GSK3β gene maps in chromosome 19 at 
position 13q.2. The GSK3β is a serine/threonine 
multifunctional protein, which is able to phosphorylate 
and inactivate glycogen synthase.(20) The GSK3β protein 
acts as an inhibitory key toward the canonical-Wnt 
signaling pathway.(21) The expression of the GSK3β 
gene attenuates the proliferation of CRC cells or leads 
to early apoptosis.(22) Therefore, under physiological 
conditions, the GSK3β phosphorylates and degrades 
protein transcription factors and oncoproteins, which 
suggests that this enzyme would be a suppressive factor 
in tumor development, which negatively interferes with 
oncogenic signaling.(21,23) It was also observed in the 
present study that the immunoreactivity of the GSK3β-
mutated protein was shown to be increased in the 
CRC and in adjacent non-neoplastic mucosa regarding 
colonic adenoma.
Axin 1 has emerged as a major scaffold protein for 
regulating a variety of signaling pathways and biological 
functions.(24) The human homolog gene of axin 1 was 
mapped to chromosome 16p13.3.(25) In sporadic CRC, 
an increased expression of axin protein suggests that 
mutation of the corresponding gene can participate in 
colorectal carcinogenesis.(26,27) In this way, the present 
study observed that the staining of the mutated protein 
GSK3β in CRC was significantly increased with respect 
to the non-neoplastic adjacent mucosa.
The ubiquitin (E3 ubiquitin ligase) is a protein that 
recruits an E2 ubiquitin-conjugating enzyme, which 
recognizes the protein substrate and assists or directly 
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catalyzes the transfer of ubiquitin from the E2 ubiquitin-
conjugating to the protein substrate.(28) The human 
homolog gene was mapped to chromosome 17p16.38.(28) 
In normal tissues, the phosphorylated beta-catenin is 
recognized by the E3 ubiquitin ligase complex forming 
the phosphorylated poly-ubiquitin/beta-catenin which 
is proteolyzed via the proteasome.(29,30)
Chen et al.(7) found that the expression of ubiquitin 
in the CCR was significantly higher than in the adjacent 
non-neoplastic mucosa, and this result was also 
found in the present study. Moreover, they observed 
no significant relation between the expression of 
ubiquitin protein and the clinical and pathological 
features of CRC, a finding that was confirmed in this 
present study.
CONCLUSION
The beta-catenin protein expression was increased in 
the cytoplasm and nucleus of the neoplastic cells, when 
compared to the colonic adenoma. The adenomatous 
polyposis coli protein was mainly altered in adenomas, 
and that, along with the increase in colorectal cancer 
of GSK3β, axin 1 and ubiquitin-mutated proteins, may 
prevent the phosphorylation of beta-catenin by the 
destroyer complex and its subsequent degradation in 
the proteasome. This event allows the stabilized beta-
catenin protein to translocate into the cell nucleus, in 
which this protein can activate transcription factors, 
as well as the expression and activation of target 
genes related to colorectal carcinogenesis. Additional 
research is needed to determine whether the ongoing 
activity of signaling pathways is required for normal and 
neoplastic tissues, and whether or not these conditions 
differ sufficiently to allow for therapeutic intervention.
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